ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

ACC 2022 Conference Coverage

P. Heidenreich

The Valve Trials Are Done: Interventional HFpEF Is the Next Big Thing

Northwestern Medicine Cardiovascular Care

S. Shah

ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

Which Diuretic(s) Are Best in HF? Update Based on Recent Clinical Tr…

MUSC Cardiology

R. Mentz

AHA 2022: Torsemide Comparison With Furosemide for Management of Hea…

AHA 2022 Conference Coverage

R. Mentz

2021 ADA Highlights: Heart Failure With Reduced Ejection Fraction - …

Michelle Kittleson

Management of Heart Failure

Obafemi Awolowo University

O. A. Akinyele

HFpEF or Amyloidosis? The Right Therapies for Right Patients

Scripps Health

M. Kittleson

Hemodynamic vs. Hemo-Metabolic Shock: Redefining Shock Profiles

The Cardiogenic Shock Working Group

N. Kapur

High-Risk Cardiac Surgery and Pre-Op Optimization with Impella Base …

St. Louis Shock & Heart Failure Symposium 2022

J. Leidenfrost

The Past, Present and Future of the Total Artificial Heart

The Texas Heart Institute

W. Cohn, O. Frazier

Contemporary Management of Cardiogenic Shock: Updates in 2022

Mount Sinai Advanced Innovations in Heart Failure

D. Baran

Hot Topics in Heart Failure ACC.22

ACC 2022 Conference Coverage

N. Ibrahim

Weight Loss as Treatment for HFpEF: An Update on Drugs and Procedures

MUSC Cardiology

S. Litwin

State of the Art Medical Therapies for Heart Failure: 2024

UCLA Health

G. Fonarow

Use of MCS in Management of Acute Post-MI VSD

Houston Shock Symposium

D. Ramini

ACC 2024 Insights: Stop the Meds! Treat the Comorbidities for Optima…

ACC 2024 Insights

K. Williams

Today's Heart Failure Clinic: A Modern Approach

UCLA Health

A. Ucla Cardiomyopathy Center

Amyloidosis Types and Pathophysiology

Houston Methodist

B. Trachtenberg